** Brokerage H.C. Wainwright starts coverage on drugmaker Ionis Pharmaceuticals IONS.O with "buy" rating and a PT of $45
** Brokerage sees upside in IONS' pending commercial launches, including Tryngolza for lowering triglycerides and Wainua for transthyretin-mediated amyloidosis (ATTR)
** Brokerage estimates that Tryngolza could serve 2.3 million patients in the U.S. and become a growth driver for the company, potentially generating $1.8 billion in sales by 2033
** 17 out of 26 brokerages rate the stock "buy" or higher, 8 rate "hold" and 1 rate "sell" and their median PT is $60 as per LSEG data
** As of last close, IONS stock down 22.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。